Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), ...
A recently cleared phase 3 study (NCT06051409) will evaluate olverembatinib combined with chemotherapy as a first-line ...
Based on the primary PFS analysis of EMBER-3, the FDA approved single-agent imlunestrant in September 2025 for the treatment of patients with ER+/HER2– ESR1 m advanced breast cancer with disease ...
The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...
Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated ...
Explore the advantages and challenges of long-term red blood cell transfusions for low-risk MDS patients, focusing on quality ...
Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...
The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.
Exploring the impact of inflammation in MDS, this article highlights the need for novel therapies to enhance patient quality ...
Robert Orlowski, MD, PhD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses prophylactic ...
Red blood cell transfusions enhance quality of life for MDS patients but require careful management to avoid complications ...
Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback